Biomarkers for the management of pre-eclampsia in pregnant women

Indian Journal of Medical Research

Volumn 138, Issue JUL 2013, 2013, Pages 60-67

  Petla, Lakshmi Tanuja ^a   Chikkala, Rosy ^a   Ratnakar, K S ^b   Kodati, Vijayalakshmi ^c   Sritharan, V ^a  

^a Molecular Diagnostics and Biomarkers Laboratory   (India)

^b Global Hospital   (India)

^c Durgabai Deshmukh Hospital and Research Centre   (India)

Author keywords

Angiogenic factors; Biomarkers; NGAL; Placenta; Pre eclampsia; Proteinuria

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; ENDOGLIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN TYROSINE KINASE; RETINOL BINDING PROTEIN 4; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN C;

BLOOD CLOTTING DISORDER; ENDOTHELIAL DYSFUNCTION; FEMALE; GESTATION PERIOD; HUMAN; PATHOGENESIS; PLACENTA DISORDER; PLACENTAL DELIVERY; PREECLAMPSIA; PREGNANCY; PRENATAL CARE; REVIEW; RISK FACTOR;

ACUTE-PHASE PROTEINS; ANTIGENS, CD; BIOLOGICAL MARKERS; FEMALE; GALECTINS; HUMANS; LIPOCALINS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84881069656     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Haig D. Genetic conflicts in human pregnancy. Q Rev Biol 1993; 68: 495-532.
2. Aernout Luttun, Peter Carmeliet. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003; 111: 600-2.
3. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008; 75: 1-8.
4. Noronha Neto C, de Souza AS, Amorim MM. Pre-eclampsia treatment according to scientific evidence. Rev Bras Ginecol Obstet 2010; 32: 459-68.
5. Arora R, Ganguli RP, Swain S, Oumachigui A, Rajaram P. Determinants of maternal mortality in eclampsia in India. Aust N Z J Obstet Gynaecol 1994; 34: 537-9.
6. Suhail M, Faizul Suhail M, Khan H. Role of vitamins C and E in regulating antioxidant and pro-oxidant markers in preeclampsia. J Clin Biochem Nutr 2008; 43: 210-20.
7. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011; 31: 33-46.
8. Maynard SE, Venkatesha S, Thadhani R, Ananth Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005; 57: 1R-7R.
9. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate a strategy for successful endovascular invasion? J Clin Invest 1997; 99: 2139-51.
10. Agarwal I, Karumanchi SA. Preeclampsia and the anti- angiogenic state. Pregnancy Hypertens 2011; 1: 17-21.
11. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009; 24: 147-58.
12. Szarka A, Rigó J Jr, Lázár L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010; 11: 59.
13. Wagner LK. Diagnosis and management of preeclampsia. Am Fam Physician 2004; 70: 2317-24.
14. Harrington K, Carpenter RG, Goldfrad C, Campbell S. Transvaginal Doppler ultrasound of the uteroplacental circulation in the early prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1997; 104: 674-81.
15. Costa FS, Murthi P, Keogh R, Woodrow N. Early screening for preeclampsia. Rev Bras Ginecol Obstet 2011; 33: 367-75.
16. Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 2008; 18: 186-94.
17. Chen Y. Novel angiogenic factors for predicting preeclampsia: sFlt-1, PlGF, and soluble endoglin. Open Clin Chem J 2009; 2: 1-6.
18. Lam C, Lim K-H, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46: 1077-85.
19. Nicolaides KH, Bindra R, Turan OM, Chefetz L, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006; 27: 13-7.
20. Molvarec A, Rigo J Jr, Lazar L, Balogh K, Mako V, Cervenak L, et al. Increased serum heat-shock protein 70 levels reflect systemic inflammation, oxidative stress and hepatocellular injury in preeclampsia. Cell Stress Chaperones 2009; 14: 151-9.
21. Molvarec A, Kalabay L, Derzsy Z, Szarka A, Halmos A, Stenczer B, et al. Preeclampsia is associated with decreased serum alpha(2)-HS glycoprotein (fetuin-A) concentration. Hypertens Res 2009; 32: 665-9.
22. Derzsy Z, Prohászka Z, Rigó J Jr, Füst G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47: 1500-6.
23. Hertig A, Liere P. New markers in preeclampsia. Clin Chim Acta 2010; 411: 1591-5.
24. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational-age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
25. Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010; 151: 122-9.
26. Molvarec A, Ito M, Shima T, Yoneda S, Toldi G, Stenczer B, et al. Decreased proportion of peripheral blood vascular endothelial growth factor-expressing T and natural killer cells in preeclampsia. Am J Obstet Gynecol 2010; 203: 567.
27. Grill S, Rusterholz C, Zanetti-Dällenbach R, Tercanli S, Holzgreve W, Hahn S, et al. Potential markers of preeclampsia - a review. Reprod Biol Endocrinol 2009; 7: 70-84.
28. Desai J, Holt-Shore V, Torry RJ, Caudle MR, Torry DS. Signal transduction and biological function of placenta growth factor in primary human trophoblast. Biol Reprod 1999; 60: 887-92.
29. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigó J Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010; 33: 892-8.
30. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.
31. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
32. Wa Law L, Sahota DS, Chan LW, Chen M, Lau TK, Leung TY. Serum placental growth factor and fms-like tyrosine kinase 1 during first trimester in Chinese women with pre-eclampsia--a case-control study. J Matern Fetal Neonatal Med 2011; 24: 808-11.
33. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74.
34. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83.
35. Bohn H, Kraus W, Winckler W. Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17). Oncodev Biol Med 1983; 4: 343-50.
36. Huppertz B, Kawaguchi R. First trimester serum markers to predict preeclampsia. Wien Med Wochenschr 2012; 162: 191-5.
37. D'Anna R, Baviera G, Giordano D, Russo S, Dugo N, Santamaria A, et al. First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia. Prenat Diagn 2009; 29: 1066-8.
38. Hawkins R. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med 2011; 31: 72-80.
39. Giasson J, Li GH, Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets 2011; 10: 272-82.
40. Uttenthal LO. NGAL: a marker molecule for the distressed kidney? Clin Lab Int 2005; 29: 39-41.
41. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly Q, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-8.
42. D'Anna R, Baviera G, Giordano D, Todarello G, Corrado F, Buemi M. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand 2008; 87: 1370-3.
43. D'Anna R, Baviera G, Giordano D, Todarello G, Russo S, Recupero S, et al. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 2010; 89: 275-8.
44. Vaisbuch E, Romero R, Mazaki-Tovi S, Erez O, Kim SK, Chaiworapongsa T, et al. Retinol binding protein 4 - a novel association with early-onset preeclampsia. J Perinat Med 2010; 38: 129-39.
45. Kalkunte S, Nevers T, Norris WE, Sharma S. Vascular IL-10: a protective role in preeclampsia. J Reprod Immunol 2011; 88: 165-9.